145 related articles for article (PubMed ID: 7923602)
21. BRCA1 up-regulation is associated with repair-mediated resistance to cis-diamminedichloroplatinum(II).
Husain A; He G; Venkatraman ES; Spriggs DR
Cancer Res; 1998 Mar; 58(6):1120-3. PubMed ID: 9515792
[TBL] [Abstract][Full Text] [Related]
22. Alterations of DNA repair in melanoma cell lines resistant to cisplatin, fotemustine, or etoposide.
Rünger TM; Emmert S; Schadendorf D; Diem C; Epe B; Hellfritsch D
J Invest Dermatol; 2000 Jan; 114(1):34-9. PubMed ID: 10620112
[TBL] [Abstract][Full Text] [Related]
23. Absence of evidence for allelic loss or allelic gain for ERCC1 or for XPD in human ovarian cancer cells and tissues.
Yu JJ; Bicher A; Ma YK; Bostick-Bruton F; Reed E
Cancer Lett; 2000 Apr; 151(2):127-32. PubMed ID: 10738106
[TBL] [Abstract][Full Text] [Related]
24. Association between cisplatin resistance and mutation of p53 gene and reduced bax expression in ovarian carcinoma cell systems.
Perego P; Giarola M; Righetti SC; Supino R; Caserini C; Delia D; Pierotti MA; Miyashita T; Reed JC; Zunino F
Cancer Res; 1996 Feb; 56(3):556-62. PubMed ID: 8564971
[TBL] [Abstract][Full Text] [Related]
25. Differential contributory roles of nucleotide excision and homologous recombination repair for enhancing cisplatin sensitivity in human ovarian cancer cells.
Wang QE; Milum K; Han C; Huang YW; Wani G; Thomale J; Wani AA
Mol Cancer; 2011 Mar; 10():24. PubMed ID: 21385444
[TBL] [Abstract][Full Text] [Related]
26. [Expression of DNA transcription- and repair-related genes in cisplatin-resistant human ovarian carcinoma cell line COC1/DDP].
Cao MM; Zhang JR; Wang SM; Hu XG; Hu LJ
Di Yi Jun Yi Da Xue Xue Bao; 2005 Dec; 25(12):1478-81. PubMed ID: 16354609
[TBL] [Abstract][Full Text] [Related]
27. Cyclosporin A suppresses cisplatin-induced c-fos gene expression in ovarian carcinoma cells.
Kashani-Sabet M; Wang W; Scanlon KJ
J Biol Chem; 1990 Jul; 265(19):11285-8. PubMed ID: 2113532
[TBL] [Abstract][Full Text] [Related]
28. Inhibition of Gli1 results in altered c-Jun activation, inhibition of cisplatin-induced upregulation of ERCC1, XPD and XRCC1, and inhibition of platinum-DNA adduct repair.
Kudo K; Gavin E; Das S; Amable L; Shevde LA; Reed E
Oncogene; 2012 Nov; 31(44):4718-24. PubMed ID: 22266871
[TBL] [Abstract][Full Text] [Related]
29. Comparative genomic hybridization analysis of chromosomal changes occurring during development of acquired resistance to cisplatin in human ovarian carcinoma cells.
Wasenius VM; Jekunen A; Monni O; Joensuu H; Aebi S; Howell SB; Knuutila S
Genes Chromosomes Cancer; 1997 Apr; 18(4):286-91. PubMed ID: 9087568
[TBL] [Abstract][Full Text] [Related]
30. Inhibition by 5-fluorouracil of ERCC1 and gamma-glutamylcysteine synthetase messenger RNA expression in a cisplatin-resistant HST-1 human squamous carcinoma cell line.
Fujishima H; Nakano S; Masumoto N; Esaki T; Tatsumoto T; Kondo T; Niho Y
Oncol Res; 1997; 9(4):167-72. PubMed ID: 9268987
[TBL] [Abstract][Full Text] [Related]
31. Development and characterization of cisplatin-resistant human testicular and bladder tumour cell lines.
Walker MC; Povey S; Parrington JM; Riddle PN; Knuechel R; Masters JR
Eur J Cancer; 1990; 26(6):742-7. PubMed ID: 2144165
[TBL] [Abstract][Full Text] [Related]
32. Characterization of a cisplatin-resistant human ovarian carcinoma cell line expressing cross-resistance to 5-fluorouracil but collateral sensitivity to methotrexate.
Hill BT; Shellard SA; Hosking LK; Dempke WC; Fichtinger-Schepman AM; Tone T; Scanlon KJ; Whelan RD
Cancer Res; 1992 Jun; 52(11):3110-8. PubMed ID: 1591724
[TBL] [Abstract][Full Text] [Related]
33. [Comparison of stepwise and pulse induced cisplatin-resistant ovarian cancer cell sublines].
Cheng G; Li Y; Tian F
Zhonghua Zhong Liu Za Zhi; 2001 Jul; 23(4):305-8. PubMed ID: 11783113
[TBL] [Abstract][Full Text] [Related]
34. Mechanism of resistance to cisplatin in a human ovarian-carcinoma cell line selected for resistance to doxorubicin: possible role of p53.
Vikhanskaya F; Clerico L; Valenti M; Stanzione MS; Broggini M; Parodi S; Russo P
Int J Cancer; 1997 Jul; 72(1):155-9. PubMed ID: 9212237
[TBL] [Abstract][Full Text] [Related]
35. Ribozyme-mediated cleavage of c-fos mRNA reduces gene expression of DNA synthesis enzymes and metallothionein.
Scanlon KJ; Jiao L; Funato T; Wang W; Tone T; Rossi JJ; Kashani-Sabet M
Proc Natl Acad Sci U S A; 1991 Dec; 88(23):10591-5. PubMed ID: 1660142
[TBL] [Abstract][Full Text] [Related]
36. Resistance of human cervical carcinoma cells to tumor necrosis factor correlates with their increased sensitivity to cisplatin: evidence of a role for DNA repair and epidermal growth factor receptor.
Nishikawa K; Rosenblum MG; Newman RA; Pandita TK; Hittelman WN; Donato NJ
Cancer Res; 1992 Sep; 52(17):4758-65. PubMed ID: 1380890
[TBL] [Abstract][Full Text] [Related]
37. Lactacystin enhances cisplatin sensitivity in resistant human ovarian cancer cell lines via inhibition of DNA repair and ERCC-1 expression.
Li QQ; Yunmbam MK; Zhong X; Yu JJ; Mimnaugh EG; Neckers L; Reed E
Cell Mol Biol (Noisy-le-grand); 2001; 47 Online Pub():OL61-72. PubMed ID: 11936875
[TBL] [Abstract][Full Text] [Related]
38. Increased nucleotide excision repair in cisplatin-resistant ovarian cancer cells: role of ERCC1-XPF.
Ferry KV; Hamilton TC; Johnson SW
Biochem Pharmacol; 2000 Nov; 60(9):1305-13. PubMed ID: 11008124
[TBL] [Abstract][Full Text] [Related]
39. Effects of RIalpha overexpression on cisplatin sensitivity in human ovarian carcinoma cells.
Cvijic ME; Chin KV
Biochem Biophys Res Commun; 1998 Aug; 249(3):723-7. PubMed ID: 9731205
[TBL] [Abstract][Full Text] [Related]
40. Tubeimoside I sensitizes cisplatin in cisplatin-resistant human ovarian cancer cells (A2780/DDP) through down-regulation of ERK and up-regulation of p38 signaling pathways.
Liu HZ; Yu C; Yang Z; He JL; Chen WJ; Yin J; Li WM; Liu HT; Wang YX
Mol Med Rep; 2011; 4(5):985-92. PubMed ID: 21687949
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
